Source-grounded facts extracted from Vera Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Vera Therapeutics, Inc. reported first quarter ended March 31, 2026 results: net income a net loss of $121.0 million, EPS a net loss per diluted share of $1.69.
“For the quarter ended March 31, 2026, Vera Therapeutics reported a net loss of $121.0 million, or a net loss per diluted share of $1.69”
Vera Therapeutics, Inc. incurred credit facility of up to $500.0 million with Oxford Finance LLC at greater of (x) the 1-Month CME Term SOFR plus 4.95% and (y) 8.70% maturing June 1, 2030, or June 1, 2031.
“On June 2, 2025 (the “Effective Date”), Vera Therapeutics, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Agreement”) with Oxford Finance LLC, as collateral agent (in such capacity, the “Collateral Agent”), and certain lenders from time to time party thereto (collectively, the “Lenders”). The Agreement provides for term loans in an aggregate principal amount of up to $500.0 million.”
David Johnson was appointed as Chief Operating Officer at Vera Therapeutics, Inc..
“On July 1, 2024, Vera Therapeutics, Inc. (the “ Company ”) announced the appointment of David Johnson as the Company’s Chief Operating Officer, effective July 1, 2024”
Christy Oliger was appointed as Director at Vera Therapeutics, Inc..
“On June 7, 2024, the board of directors (the “Board”) of Vera Therapeutics, Inc. (the “Company”) appointed Christy Oliger to the Board, effective immediately.”
Vera Therapeutics, Inc. shareholders approved Ratification of the Selection of KPMG LLP as the independent registered public accounting firm at the 2024-05-15 meeting.
“Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024.”
Vera Therapeutics, Inc. shareholders approved Election of Directors at the 2024-05-15 meeting.
“Proposal 1. Election of Directors The Company’s stockholders elected the three persons listed below as Class III Directors, each to serve until the Company’s 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or, if sooner, such director’s death, resignation or removal.”
Vera Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: net income net loss of $28.4 million, or a net loss per diluted share of $0.56, EPS net loss per diluted share of $0.56.
“For the quarter ended March 31, 2024, the company reported a net loss of $28.4 million, or a net loss per diluted share of $0.56, compared to a net loss of $30.1 million, or a net loss per diluted share of $0.80, for the same period last year.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.